CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 20 enrolled
Drug / intervention
Lovastatindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02563860
NCT02563860Phase 2Completed
CompareCT.gov

Pharmacological Treatment of Rett Syndrome With 3-Hydroxy-3 Methylglutaryl-coenzyme A Reductase Inhibitor-Lovastatin (Mevacor)

Montefiore Medical Center·interventional·Posted Sep 30, 2015·Updated Jul 12, 2019

In Brief

A Phase 2 clinical trial evaluating Lovastatin for Rett Syndrome. Completed, enrolled 20 participants across 1 site.

Detailed Summary

This is a phase 2 , open label, dose escalating study of Lovastatin in Rett syndrome.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRett Syndrome
CountriesUnited States
CollaboratorsRett Syndrome Research Trust

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedSep 30, 2015
Enrollment StartJul 1, 2015
Primary CompletionJul 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 10.8 years ago

Interventions

Lovastatindrug

dose escallating